WELCOME TO The HEALTHCARE REPORT
Newsletter | Member Login | Signup
Home > Companies > Cape Cod Healthcare
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Future of Healthcare
DocGo | May 06, 2022
DocGo has signed a contract with Empire BlueCross BlueShield to provide mobile health services to Empire BlueCross BlueShield members in New York and New Jersey. DocGo is a major last-mile mobile health service company that has offered integrated medical transportation solutions to various other healthcare service companies and organizations. DocGo operates in 28 U.S. states and the United Kingdom, providing Mobile Health services at scale. The services are solely dedicated to gover...
Digital Healthcare
Purpose Investments | January 19, 2022
Purpose Investments Inc. (“Purpose Investments” or “Purpose”) is pleased to announce the launch of Purpose Healthcare Innovation Yield ETF (the “Fund”). The Fund has closed the offering of its initial units, and units of the Fund will begin trading today on the Toronto Stock Exchange under the ticker, HEAL. The Fund is the first of its kind in Canada to provide actively managed exposure to innovation leaders in biotech and healthcare. The recent a...
Medical Devices
ASEP Medical Holdings Inc | November 25, 2022
Asep Medical Holdings Inc. is pleased to announce that, for recruitment, incentivization, and retention purposes, it has granted to certain officers and advisors an aggregate of 1,080,000 stock options to purchase up to 1,080,000 common shares of the Company of which 200,000 are exercisable at a price of $0.30 per Share until September 29, 2032, 200,000 are exercisable at a price of $0.30 per share until October 1, 2032, and 680,000 are exercisable at a price of $0.30 per share until November...
GNS Healthcare | July 22, 2020
GNS Healthcare (GNS), a leading AI and simulation company, presents results that validate the use of AI to accurately classify tumors based on their immunogenicity and predict response to immune checkpoint inhibitor (ICI) therapy using real-world data. The study showcases the power of causal AI to capture biomarkers and mechanisms, in addition to PD(L)1 and tumor mutation burden (TMB), that are consistent with known immunology. These markers, including CXCL13 upregulation and STK11 mutation, are...
Healthtech Security
Article
Video
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE